Cytokines, Chemokines & Receptors

Cat. No.

AT0967

CAS No.

2416593-08-1

Anumigilimab

Synonyms: CSL-324

Anumigilimab (CSL-324) is a human IgG4 monoclonal antibody targeting the granulocyte colony-stimulating factor (G-CSF) receptor. This antibody is designed to modulate immune responses by increasing the recruitment of neutrophils to sites of inflammation. Anumigilimab is primarily utilized in research focused on the mechanisms of neutrophil mobilization and the inflammatory response, offering potential insights into therapeutic strategies for diseases characterized by acute or chronic inflammation.

Cat. No.

AT0973

CAS No.

3018901-76-0

Arumakimig

Arumakimig is a bispecific humanized antibody designed to target and neutralize both interleukin-18 (IL-18) and interleukin-1β (IL-1β). This dual specificity makes it an invaluable tool for research focused on inflammation and immune response modulation. Arumakimig is particularly suited for studies investigating the pathophysiology of diseases characterized by excessive or dysregulated inflammation, offering insights into potential therapeutic interventions.

Cat. No.

AT1004

CAS No.

2911580-96-4

Afimkibart

Synonyms: PF-06480605; RVT-3101

Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody that specifically targets tumor necrosis factor-like ligand 1A (TL1A). This antibody is designed for use in research focused on inflammatory bowel disease, providing a valuable tool for investigating the role of TL1A in inflammation and immune response.

Cat. No.

AT1020

Anti-CSF3R/G-CSFR Antibody

The Anti-CSF3R/G-CSFR Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CSF3R/G-CSFR receptor. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is ideal for detailed studies on the biological functions and signaling pathways mediated by the CSF3R/G-CSFR receptor, which is pivotal in the regulation of granulocyte production and function.

Cat. No.

AT1026

CAS No.

2171034-71-0

Dovanvetmab

Synonyms: ZTS-00521505

Dovanvetmab, designated as ZTS-00521505, is a recombinant monoclonal antibody of the IgG1-κ isotype. It specifically targets feline interleukin-31 (Felcat IL31), a cytokine implicated in signaling pathways that mediate pruritus and inflammation in cats. This antibody is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and consistency in antibody structure and function. Dovanvetmab is utilized primarily in veterinary research, focusing on the pathophysiology and potential therapeutic interventions for feline allergic and inflammatory conditions.

Cat. No.

AT1028

CAS No.

2226742-52-3

Itepekimab

Synonyms: REGN-3500; SAR-440340

Itepekimab (REGN-3500) is an IgG4 monoclonal antibody that targets interleukin-33 (IL-33). This antibody has demonstrated efficacy in reducing airway inflammation and associated tissue damage in early clinical trials. It holds therapeutic potential for a range of inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). The specificity of Itepekimab for IL-33 makes it a promising candidate for further research and development in the management of these diseases.

Cat. No.

AT1032

CAS No.

2839417-54-6

Lanerkitug

Lanerkitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets CCR8. For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control. This specificity makes Lanerkitug suitable for research focused on the role of CCR8 in immune responses and potential therapeutic applications.

Cat. No.

AT1041

CAS No.

815610-63-0

Ustekinumab

Synonyms: Anti-Human IL-12/IL-23; Human Antibody

Ustekinumab is a human monoclonal antibody of the IgG1κ subclass that targets interleukin-12 (IL-12) and interleukin-23 (IL-23). This biologic is engineered to bind specifically to the p40 protein subunit shared by these cytokines, thereby inhibiting their interaction with the IL-12Rβ1 receptor and modulating immune responses involved in inflammatory pathways. Ustekinumab is utilized primarily in the study of immune-mediated disorders and has applications in the research of diseases such as psoriasis, Crohn’s disease, and other chronic inflammatory conditions.

Cat. No.

AT1052

CAS No.

1143503-69-8

Ixekizumab

Synonyms: LY2439821

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.

Cat. No.

AT1061

CAS No.

2803351-66-6

Ocankitug

Ocankitug is a humanized IgG1κ monoclonal antibody specifically targeting thymic stromal lymphopoietin (TSLP). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT1068

CAS No.

2226654-05-1

Ziltivekimab

Synonyms: COR-001; MEDI-5117

Ziltivekimab (COR-001) is a humanized monoclonal antibody designed to target interleukin-6 (IL-6), a cytokine known to play a critical role in systemic inflammation. This antibody has demonstrated efficacy in lowering serum C-reactive protein (CRP) levels, indicating its potent anti-inflammatory properties. Ziltivekimab is primarily utilized in research focused on chronic systemic inflammation, particularly in conditions such as chronic kidney disease (CKD) and cardiovascular diseases, including atherosclerosis. Its specific interaction with IL-6 makes it a valuable tool for studies exploring the pathophysiology and potential therapeutic interventions for these diseases.

Cat. No.

AT1070

CAS No.

2922866-66-6

Denrakibart

Denrakibart is a human monoclonal antibody of the IgG2κ subtype that specifically targets CCL17. For experimental control purposes, it is recommended to use Human IgG2 kappa as the isotype control.

Cat. No.

AT1072

CAS No.

2222865-46-3

Melrilimab

Synonyms: GSK 3772847; CNTO-7160

Melrilimab (GSK 3772847) is a monoclonal antibody of the IgG2-kappa subclass that targets IL1RL1, also known as ST2, IL33R, DER4, and FIT-1. This antibody is specifically designed for the investigation of its role in asthma pathogenesis and potential therapeutic applications.

Cat. No.

AT1073

CAS No.

2925270-26-2

Drotokibart

Drotokibart is a humanized IgG4κ monoclonal antibody that specifically targets the IL4RA protein. For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and control recommendation ensure precise and reliable results in research applications focusing on the IL4RA pathway.

Cat. No.

AT1075

CAS No.

1399584-78-1

Romilkimab

Synonyms: SAR156597

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin antibody engineered to specifically target both interleukin-4 (IL-4) and interleukin-13 (IL-13). This dual specificity allows for potential therapeutic applications in treating diseases characterized by overactive IL-4 and IL-13 pathways, such as certain inflammatory and autoimmune disorders.

Cat. No.

AT1083

CAS No.

375348-49-5

Bertilimumab

Synonyms: CAT 213; iCo-008

Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody specifically designed to target eotaxin-1 (CCL11), a key chemokine involved in the recruitment of eosinophils to inflammatory sites. This antibody has significant potential for the study of allergic disorders, offering a precise tool for elucidating the role of eotaxin-1 in the pathogenesis of these conditions. Bertilimumab may facilitate the development of therapeutic strategies aimed at modulating immune responses in allergic diseases.

Cat. No.

AT1094

CAS No.

2640257-30-1

Lunlekitug

Lunlekitug is a human monoclonal antibody of the IgG1κ subtype that specifically targets interleukin-1 alpha (IL1A). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is designed for use in research studies examining the role and modulation of IL1A in various biological processes and disease states.

Cat. No.

AT1095

Anti-CXCL8/IL-8 Antibody

The Anti-CXCL8/IL-8 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CXCL8/IL-8 chemokine. This antibody is structured with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is essential for research focused on inflammatory responses and chemotactic processes involving CXCL8/IL-8.

Cat. No.

AT1098

Anti-CXCR4/CD184 Antibody

The Anti-CXCR4/CD184 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXCR4/CD184 receptor, a chemokine receptor implicated in various biological processes including cell migration, hematopoiesis, and tumor metastasis. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Cat. No.

AT1103

CAS No.

2415207-91-7

Ecleralimab

Synonyms: CSJ-117; NVP-CSJ117

Ecleralimab (CSJ-117; NVP-CSJ117) is a recombinant monoclonal antibody of the Fab-IgG1-λ2 subtype, specifically designed to target thymic stromal lymphopoietin (TSLP). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in its structure and function. Ecleralimab is utilized primarily in research focused on understanding TSLP's role in immune response and potential therapeutic interventions.

Cat. No.

AT1106

CAS No.

2241728-76-5

Torudokimab

Torudokimab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-33 (IL-33). This antibody is constructed with a human IgG4SP heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.22 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended.

Cat. No.

AT1117

CAS No.

1612838-76-2

Risankizumab

Synonyms: Risankizumab rzaa; BI 655066

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), exhibiting a high binding affinity with a dissociation constant (Kd) of less than 10 pM. This antibody effectively inhibits the production of interleukin-17 (IL-17) induced by IL-23 in mouse splenocytes, demonstrating a half-maximal inhibitory concentration (IC50) of 2 pM. Risankizumab is primarily utilized in research focused on immunological and inflammatory disorders, including psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis, providing a valuable tool for understanding the pathophysiology and potential therapeutic interventions for these conditions.

Cat. No.

AT1119

NI-0801

NI-0801 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CXCL10/IP-10. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT1124

Anti-IL-12 p70 Antibody (20C2)

The Anti-IL-12 p70 Antibody (20C2) is a chimeric rat IgG1, κ antibody specifically designed to target human IL-12 p70. For accurate experimental control, the recommended isotype control is Rat IgG1 kappa, Isotype Control. This antibody facilitates detailed study of IL-12 p70's role in immunological responses and its potential implications in inflammatory diseases.

Cat. No.

AT1128

CAS No.

272780-74-2

Metelimumab

Synonyms: CAT-192; Anti-TGFB1 Recombinant Antibody

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody engineered to selectively neutralize transforming growth factor beta 1 (TGFβ1). This specificity makes it a valuable tool for researchers studying fibrosis, cancer progression, and other TGFβ1-related pathologies.